Nubeqa
Generic name:darolutamide [ DAR-oh-LOO-ta-mide ]
Drug classes:Antiandrogens, Hormones / antineoplastics
What is Nubeqa?
Nubeqa a prescription medicine used to treat prostate cancer that has not spread to other parts of your body.
Nubeqa is given after surgery or other treatments did not work or have stopped working.
It is not known if Nubeqa is safe and effective in children or in females.
Warnings
Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.
Before taking this medicine
To make sure Nubeqa is safe for you, tell your doctor if you have ever had:
liver or kidney disease.
Darolutamide may harm an unborn baby or cause a miscarriage. Nubeqa is not for use by women. Use effective birth control if your sex partner is able to get pregnant. Keep using birth control for at least 1 week after your last dose. Tell your doctor right away if a pregnancy occurs while you are using Nubeqa.
It may be harder for you to get a woman pregnant while you are using Nubeqa. You should still use birth control to prevent pregnancy because the medicine can harm an unborn baby.
Nubeqa is not for use by women or by anyone younger than 18 years old.
How should I take Nubeqa?
Take Nubeqa exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets.
Take with food.
Swallow the tablet whole and do not crush, chew, or break it.
If you have not had castration surgery (to lower the amount of testosterone in your body), your doctor may also prescribe a gonadotropin-releasing hormone (GnRH) medicine such as Eligard, Lupron, Trelstar, Zoladex, or Vantas. Keep using your GnRH as directed.
Store at room temperature away from moisture and heat. Keep the bottle tightly closed when not in use.
Dosing information
Usual Adult Dose for Prostate Cancer:
600 mg orally 2 times a day
Comments:
-Patients receiving this drug should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy.
Use: For nonmetastatic castration resistant prostate cancer (nmCRPC)
